OncoMatch/Clinical Trials/NCT04596670
68Ga-ICAM-1pep PET/CT in Cancer Patients
Is NCT04596670 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies 68Ga-ICAM-1pep for cancer.
Treatment: 68Ga-ICAM-1pep — This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the clinical predictive value of 68Ga-ICAM-1pep in metastatic cancer patients receiving radiotherapy. A single dose of 2.96 MBq/kg body weight of 68Ga-ICAM-1pep will be injected intravenously. The visual and semiquantitative methods will be used to assess the PET/CT images.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Low WBC (less than 3 x 10^9/L) excluded
Kidney function
severe renal dysfunction excluded
Liver function
severe hepatic dysfunction excluded
Severe hepatic or renal dysfunction; Low WBC (less than 3 x 10^9/L)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify